Telemetry Investments L.L.C. bought a new position in Stemline Therapeutics Inc (NASDAQ:STML) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 41,588 shares of the biopharmaceutical company’s stock, valued at approximately $395,000. Telemetry Investments L.L.C. owned about 0.13% of Stemline Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC grew its stake in shares of Stemline Therapeutics by 11.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 29,723 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 2,982 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Stemline Therapeutics in the fourth quarter worth $47,000. MetLife Investment Advisors LLC grew its stake in shares of Stemline Therapeutics by 54.6% in the third quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock worth $307,000 after acquiring an additional 6,527 shares during the last quarter. Neuberger Berman Group LLC grew its stake in shares of Stemline Therapeutics by 15.2% in the third quarter. Neuberger Berman Group LLC now owns 60,500 shares of the biopharmaceutical company’s stock worth $1,004,000 after acquiring an additional 8,000 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Stemline Therapeutics by 97.8% in the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 10,159 shares during the last quarter. 64.82% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on the company. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Stemline Therapeutics in a research report on Wednesday, February 6th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stemline Therapeutics in a research report on Friday, January 25th. ValuEngine cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Finally, BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 27th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Stemline Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.40.

Shares of Stemline Therapeutics stock traded up $0.19 during trading on Friday, hitting $13.66. 9,151 shares of the company’s stock traded hands, compared to its average volume of 727,132. Stemline Therapeutics Inc has a 1 year low of $7.82 and a 1 year high of $20.55. The stock has a market capitalization of $429.62 million, a PE ratio of -4.66 and a beta of 1.12.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 13,547 shares of the firm’s stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $10.15, for a total value of $137,502.05. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Ivan Bergstein sold 34,132 shares of the firm’s stock in a transaction dated Thursday, February 14th. The stock was sold at an average price of $10.98, for a total value of $374,769.36. The disclosure for this sale can be found here. Insiders sold 100,880 shares of company stock worth $1,145,287 over the last three months. Insiders own 14.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Telemetry Investments L.L.C. Invests $395,000 in Stemline Therapeutics Inc (STML)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2019/03/15/telemetry-investments-l-l-c-invests-395000-in-stemline-therapeutics-inc-stml.html.

Stemline Therapeutics Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Read More: Mutual Funds

Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics Inc (NASDAQ:STML).

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.